Pfizer Other Current Assets 2010-2024 | PFE
Pfizer other current assets from 2010 to 2024. Other current assets can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Pfizer other current assets for the quarter ending September 30, 2024 were $7.098B, a 16.89% decline year-over-year.
- Pfizer other current assets for 2023 were $9.277B, a 7.95% increase from 2022.
- Pfizer other current assets for 2022 were $8.594B, a 124.97% increase from 2021.
- Pfizer other current assets for 2021 were $3.82B, a 4.77% increase from 2020.
Pfizer Annual Other Current Assets
(Millions of US $) |
| 2023 |
$9,277 |
| 2022 |
$8,594 |
| 2021 |
$3,820 |
| 2020 |
$3,646 |
| 2019 |
$2,357 |
| 2018 |
$12,186 |
| 2017 |
$5,351 |
| 2016 |
$6,091 |
| 2015 |
$4,825 |
| 2014 |
$2,843 |
| 2013 |
$3,689 |
| 2012 |
$3,567 |
| 2011 |
$9,380 |
| 2010 |
$9,440 |
| 2009 |
$496 |
Pfizer Quarterly Other Current Assets
(Millions of US $) |
| 2024-09-30 |
$7,098 |
| 2024-06-30 |
$7,884 |
| 2024-03-31 |
$8,605 |
| 2023-12-31 |
$8,889 |
| 2023-09-30 |
$8,541 |
| 2023-06-30 |
$8,022 |
| 2023-03-31 |
$8,260 |
| 2022-12-31 |
$8,594 |
| 2022-09-30 |
$6,149 |
| 2022-06-30 |
$5,970 |
| 2022-03-31 |
$4,202 |
| 2021-12-31 |
$3,820 |
| 2021-09-30 |
$7,667 |
| 2021-06-30 |
$7,579 |
| 2021-03-31 |
$7,510 |
| 2020-12-31 |
$3,646 |
| 2020-09-30 |
$6,519 |
| 2020-06-30 |
$2,513 |
| 2020-03-31 |
$2,737 |
| 2019-12-31 |
$2,357 |
| 2019-09-30 |
$6,713 |
| 2019-06-30 |
$12,412 |
| 2019-03-31 |
$12,444 |
| 2018-12-31 |
$12,186 |
| 2018-09-30 |
$2,450 |
| 2018-06-30 |
$2,343 |
| 2018-03-31 |
$2,190 |
| 2017-12-31 |
$5,351 |
| 2017-09-30 |
$2,174 |
| 2017-06-30 |
$1,880 |
| 2017-03-31 |
$2,221 |
| 2016-12-31 |
$6,091 |
| 2016-09-30 |
$3,962 |
| 2016-06-30 |
$3,023 |
| 2016-03-31 |
$2,355 |
| 2015-12-31 |
$4,825 |
| 2015-09-30 |
$2,248 |
| 2015-06-30 |
$2,449 |
| 2015-03-31 |
$2,815 |
| 2014-12-31 |
$2,843 |
| 2014-09-30 |
$2,545 |
| 2014-06-30 |
$2,727 |
| 2014-03-31 |
$3,473 |
| 2013-12-31 |
$3,689 |
| 2013-09-30 |
$7,835 |
| 2013-06-30 |
$9,819 |
| 2013-03-31 |
$9,647 |
| 2012-12-31 |
$3,567 |
| 2012-09-30 |
$8,849 |
| 2012-06-30 |
$9,215 |
| 2012-03-31 |
$9,361 |
| 2011-12-31 |
$9,380 |
| 2011-09-30 |
$9,288 |
| 2011-06-30 |
$9,271 |
| 2011-03-31 |
$8,755 |
| 2010-12-31 |
$9,440 |
| 2010-09-30 |
$494 |
| 2010-06-30 |
$682 |
| 2010-03-31 |
$490 |
| 2009-12-31 |
$496 |
| 2009-09-30 |
$231 |
| 2009-06-30 |
$219 |
| 2009-03-31 |
$299 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
